methyl 1-allyl-3-cyclohexyl-2-(2-vinylphenyl)-1H-indole-6-carboxylate | 877271-37-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: methyl 1-allyl-3-cyclohexyl-2-(2-vinylphenyl)-1H-indole-6-carboxylate
• 英文别名: methyl 3-cyclohexyl-2-(2-vinylphenyl)-1-(2-propenyl)-indole-6-carboxylate；methyl 1-allyl-3-cyclohexyl-2-(2-vinylphenyl)1H-indole-6-carboxylate；methyl 3-cyclohexyl-2-(2-ethenylphenyl)-1-prop-2-enylindole-6-carboxylate
• CAS: 877271-37-9
• 化学式: C₂₇H₂₉NO₂
• 分子量: 399.533
• InChiKey: SKKQLURWDQITCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 1-allyl-3-cyclohexyl-2-(2-vinylphenyl)-1H-indole-6-carboxylate 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 10% palladium on activated charcoal 、 水 、 氢气 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 0.17h， 生成 13-cyclohexyl-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid
  参考文献：
  名称：

  Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus

  摘要：

  Herein, we present initial SAR studies on a series of bridged 2-arylindole-based NS5B inhibitors. The introduction of bridging elements between the indole N1 and the ortho-position of the 2-aryl moiety resulted in conformationally constrained heterocycles that possess multiple additional vectors for further exploration. The binding mode and pharmacokinetic (PK) properties of select examples, including: 13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[2,1-d][1,4]benzodiazepine-10-carboxylic acid (7) (IC50 = 0.07 mu M, % F = 18), are reported. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.067
• 作为产物：
  描述：

  2-溴-3-环己基-1H-吲哚-6-羧酸甲酯 在 四(三苯基膦)钯 、 sodium hydride 、 sodium carbonate 、 lithium chloride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 methyl 1-allyl-3-cyclohexyl-2-(2-vinylphenyl)-1H-indole-6-carboxylate
  参考文献：
  名称：

  Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus

  摘要：

  Herein, we present initial SAR studies on a series of bridged 2-arylindole-based NS5B inhibitors. The introduction of bridging elements between the indole N1 and the ortho-position of the 2-aryl moiety resulted in conformationally constrained heterocycles that possess multiple additional vectors for further exploration. The binding mode and pharmacokinetic (PK) properties of select examples, including: 13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[2,1-d][1,4]benzodiazepine-10-carboxylic acid (7) (IC50 = 0.07 mu M, % F = 18), are reported. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.067

文献信息

• Inhibitors of HCV replication
  申请人：Hudyma W. Thomas

  公开号：US20060046983A1

  公开（公告）日：2006-03-02

  Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.

  化合物I的吲哚类化合物已被描述。这些化合物对丙型肝炎病毒（HCV）具有活性，并可用于治疗感染HCV的人。还描述了包含这些化合物的不同形式和组成，以及制备这些化合物的方法。
• Synthesis of Indolo[2,1-<i>a</i>][2]benzazepine and Indolo[2,1-<i>a</i>][2]-benzazocine
  作者：Simona Ponzi、Jörg Habermann、Maria del Rosario Rico Ferreira、Frank Narjes

  DOI：10.1055/s-0029-1217168

  日期：——

  The synthesis of functionalised 6,7-dihydro-5H-indolo[2,1-a][2]benzazepine and 5,6,7,8-tetrahydroindolo[2,1-a][2]benz­azocine from methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxy­late, involving RCM as the key step to generate the tetracyclic indolo[2,1-a][2]benzazepine and indolo[2,1-a][2]benzazocine core structure, is outlined.

  以甲基2-溴为原料合成功能化6,7-二氢-5H-吲哚并[2,1-a][2]苯并氮杂卓和5,6,7,8-四氢吲哚并[2,1-a][2]苯并佐辛-3-环己基-1H-吲哚-6-羧酸酯，以RCM为关键步骤生成四环吲哚并[2,1-a][2]苯并氮杂卓和吲哚[2,1-a][2]苯并佐辛核心结构，已概述。
• Tetracyclic Indole Derivatives as Antiviral Agents
  申请人：Ercolani Caterina

  公开号：US20080261938A1

  公开（公告）日：2008-10-23

  The present invention relates to tetracyclic indole compounds of formula (I); wherein R 1 , R 2 , R 14 , R 15 , A, Ar, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.

  本发明涉及式(I)的四环吲哚化合物；其中R1、R2、R14、R15、A、Ar、Y和Z在此定义，以及其药学上可接受的盐、包括它们的制药组合物，以及它们用于治疗或预防丙型肝炎病毒感染的用途。
• Tetracyclic indole derivatives as antiviral agents
  申请人：Istituto di Richerche di Biologia Molecolare P Angeletti SpA

  公开号：US07662809B2

  公开（公告）日：2010-02-16

  The present invention relates to tetracyclic indole compounds of formula (I); wherein R1, R2, R14, R15, A, Ar, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.

  本发明涉及式(I)的四环吲哚化合物；其中R1、R2、R14、R15、A、Ar、Y和Z在此定义，并且其药学上可接受的盐，包括它们的制药组合物，以及它们用于治疗或预防丙型肝炎病毒感染的用途。
• WO2007/92000
  申请人：——

  公开号：——

  公开（公告）日：——